A Rare Case Seen in a Patient with Intravesical Bacillus Calmette-Guerin (BCG) Intolerance: Autoimmune Myopathy

Author:

ÇEKER Gökhan1ORCID,AKDUMAN Bülent2ORCID

Affiliation:

1. Başakşehir Çam ve Sakura Şehir Hastanesi, Üroloji Kliniği

2. Zonguldak Bülent Ecevit Üniversitesi Tıp Fakültesi Üroloji Anabilim Dalı

Abstract

Aim: We present a case of autoimmune myopathy observed in a patient who developed intolerance to intravesical Bacillus Calmette-Guerin (BCG), which is used in the treatment of non-muscle invasive bladder cancer. Case: Intravesical BCG, which is used for the treatment of non-muscle invasive bladder cancer, probably effects by increasing autoimmunity in the bladder. This increased autoimmunity sometimes causes local or systemic reactions. In this case report, we would like to present a 61-year-old male patient who developed intolerance while taking the first dose of maintenance BCG, and then on-going treatment was stopped. The patient had convulsive painful cramps and muscle twitches in the left quadriceps femoris region one month later BCG intolerance. When the patient’s anamnesis, electromyography (EMG) results, elevated Creatine Kinase value and other laboratory data were evaluated together, BCG triggered autoimmune myopathy was considered. Therefore, steroid treatment was started and the patient recovered seven weeks later. This is a rare case of autoimmune myopathy in a patient who received intravesical BCG therapy for a bladder tumor. Conclusion: The case of BCG-associated autoimmune myopathy is extremely rare. When this situation is suspected, it is beneficial to start steroid treatment without delay.

Funder

Yok

Publisher

Bulent Evcevit University

Reference13 articles.

1. 1. International Agency for Research on Cancer, W.H.O., 2021. Estimated number of new cases in 2020, worldwide, both sexes, all ages. Cancer Today. https://gco. iarc. fr/today/onlineanalysis- table.

2. 2. Gontero P, Compérat EM, Escrig Dominguez JL, Liedberg F, Mariappan P, Masson-Lecomte A, Mostafid AH, van Rhijn BWG, Rouprét M, Seisen T, Shariat SF, Xylinas EN. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS) – 2023 edition.

3. 3. Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer-a current perspective. Nat Publ Gr 2014;11:153–62. doi:10.1038/ nrurol.2014.15.

4. 4. Green DB, Kawashima A, Menias CO, Tanaka T, Redelman- Sidi G, Bhalla S, Shah R, King BF. Complications of intravesical BCG immunotherapy for bladder cancer. Radiographics 2019;39(1):80-94.

5. 5. Luca S, Mihaescu T. History of BCG Vaccine. Maedica (Bucur) 2013;8(1):53-58

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3